Hutchmed: Bullish On Their Commercial Prospects And Pipeline Catalysts

Hutchmed basically combines a growing oncology franchise with late-stage immunology assets and an early ATTC pipeline. Their Fruzaqla international rollout and improving China execution could also help increase their recurring revenues. Similarly, Sovleplenib, Fanregratinib, and SAFFRON give HCM several options to further derisk its broader pipeline. HCM also has a highly liquid balance sheet and doesn’t appear excessively valued. So, I rate HCM a viable speculative “Buy” at these levels.

HUTCHMED (China) Limited ( HCM ) is a Hong Kong-based biopharmaceutical company that has in-house drug discovery. However, they also have interesting commercial oncology operations and royalty-generating partnerships. Their partnerships are mainly with Takeda.